EXAGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.412 USD | +0.15% |
|
+3.07% | -29.04% |
| Apr. 26 | Exagen Inc. Announces Changes in Board of Directors | CI |
| Mar. 18 | Exagen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Presentation Operator MessageOperator (Operator)Greetings. Welcome to the Exagen Inc. Second Q...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Exagen Inc. is a provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision-making. The Company has developed and is commercializing a portfolio of testing products, under its AVISE brand. It commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.412
USD
Average target price
5.5
USD
Spread / Average Target
+289.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.04% | 24.34M | |
| -14.92% | 84.68B | |
| +13.30% | 81.12B | |
| +10.92% | 29.4B | |
| -12.71% | 16.73B | |
| -3.06% | 16.36B | |
| -2.63% | 14.92B | |
| -31.75% | 11.77B | |
| -1.42% | 11.72B | |
| +27.44% | 11.71B |
- Stock Market
- Equities
- XGN Stock
- News Exagen Inc.
- Transcript : Exagen Inc., Q2 2023 Earnings Call, Aug 07, 2023
